Pages that link to "Q43830854"
Jump to navigation
Jump to search
The following pages link to Adverse drug reaction labelling for atomoxetine, methylphenidate and modafinil: comparison of product information for oral formulations in Australia, Denmark and the United States (Q43830854):
Displaying 6 items.
- Identification of possible adverse drug reactions in clinical notes: The case of glucose-lowering medicines (Q30002304) (← links)
- Variation in adverse drug reactions listed in product information for antidepressants and anticonvulsants, between the USA and Europe: a comparison review of paired regulatory documents (Q36707414) (← links)
- Effects of methylphenidate on appetite and growth in children diagnosed with attention deficit and hyperactivity disorder. (Q48135974) (← links)
- Comparison of pregnancy and lactation labeling for attention-deficit hyperactivity disorder drugs marketed in Australia, the USA, Denmark, and the UK. (Q50562224) (← links)
- Comparative Analysis of ADR on China's National Essential Medicines List (2015 Edition) and WHO Model List of Essential Medicines (19th Edition). (Q55450550) (← links)
- Consistency of listed indications and contraindications between the U.S., the U.K., Japan, and Korea on prescription drug labels (Q57214436) (← links)